Sudeep Pharma reported its highest-ever quarterly revenue of INR 196 crore for Q2 FY27, a 21% jump YoY. While EBITDA margins expanded to 37.2%, the company navigated logistics headwinds and a temporary pause in the government's fortified rice program. Key catalysts include the recent US FDA approval for its Nandesari facility and ongoing progress in its battery materials segment, with commercial production slated for April 2027.
Sudeep Pharma Q2 FY27 Financial Results
Revenue: INR 196 Cr | EBITDA: INR 73 Cr
Reader Takeaway: Strong core pharma demand and new capacity drive growth, but logistics costs and policy pauses remain.
What just happened
Sudeep Pharma has posted record-breaking financial performance for the second quarter of FY27. Revenue surged 21% year-on-year to INR 196 crore, while EBITDA climbed 32% to reach INR 73 crore. The company successfully expanded its EBITDA margin by 310 basis points to 37.2%, despite absorbing INR 8 crore in additional freight expenses.
Why this matters
The company is proving its ability to scale high-margin segments like Pharma Food Nutrition (PFN), which now accounts for 72% of total revenue. The PFN segment saw significant growth, with revenue up 57% and margins expanding to 41%. The recent US FDA approval of the Nandesari greenfield facility provides a strategic base for high-value product manufacturing starting in the second half of the year.
The backstory
Historically, Sudeep Pharma has focused on ingredient solutions for the pharma and food industries. The recent pivot toward battery materials with its Dahej project marks a new growth phase. Phase 1 of this project is expected to deliver 25,000 tons of battery-grade iron phosphate by April 2027, with long-term plans to scale capacity up to 200,000 tons.
Risks to watch
The specialty ingredients segment faced a temporary revenue dip due to the pause in the government's fortified rice program. Furthermore, net working capital remains high at 214 days, though management aims to optimize this to under 180 days. Elevated global freight costs continue to act as a margin pressure point.
What to track next
Investors should look for updates on firm offtake agreements for the Dahej battery materials facility. Additionally, the speed of production ramp-up at the new Nandesari facility will be a critical indicator of future revenue acceleration.